Cost vs Efficacy · 4 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Tegafur, Uracil, Folinic acid Variant #01 Partial | — | R 2 956 | 35d | — | — | — | — | — |
mFOLFOX6 Variant #02 | — | R 2 466 | 14d | ~9.5 mo | ~23.3 mo | ~21 | ~R 51 796 PFS proxy · indirect | 9 |
CapeOx Variant #01 | — | R 2 384 | 21d | ~6.7 mo | ~19.9 mo | ~10 | ~R 23 842 PFS proxy · indirect | 3 |
Capecitabine monotherapy Variant #17 | — | R 2 219 | 21d | ~5.7 mo | — | ~9 | ~R 19 974 PFS proxy · indirect | 5 |
mFOLFOX6 (L-Leucovorin) Variant #01 Partial | — | R 1 629 | 14d | — | ~20.7 mo | — | — | 2 |
FULV Variant #01 | — | R 1 466 | 35d | ~6.2 mo | ~13.2 mo | ~6 | ~R 8 795 PFS proxy · indirect | 6 |
FULV (L-Leucovorin) Variant #06 Partial | — | R 825 | 14d | — | ~6.1 mo | — | — | 1 |
Observation Partial | — | — | — | ~3.4 mo | — | — | — | 2 |
8 of 8 regimens shown